Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists

British Journal of Pharmacology
David WinpennyDarren Cawkill

Abstract

Biased GPCR ligands are able to engage with their target receptor in a manner that preferentially activates distinct downstream signalling and offers potential for next generation therapeutics. However, accurate quantification of ligand bias in vitro is complex, and current best practice is not amenable for testing large numbers of compound. We have therefore sought to apply ligand bias theory to an industrial scale screening campaign for the identification of new biased μ receptor agonists. μ receptor assays with appropriate dynamic range were developed for both Gαi -dependent signalling and β-arrestin2 recruitment. Δlog(Emax /EC50 ) analysis was validated as an alternative for the operational model of agonism in calculating pathway bias towards Gαi -dependent signalling. The analysis was applied to a high throughput screen to characterize the prevalence and nature of pathway bias among a diverse set of compounds with μ receptor agonist activity. A high throughput screening campaign yielded 440 hits with greater than 10-fold bias relative to DAMGO. To validate these results, we quantified pathway bias of a subset of hits using the operational model of agonism. The high degree of correlation across these biased hits confirmed t...Continue Reading

References

Dec 22, 1983·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·J W Black, P Leff
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·J ZhangM G Caron
Sep 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Huijun WeiRobert J Lefkowitz
Sep 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Mounia AzziGraciela Piñeyro
May 27, 2005·The Journal of Pharmacology and Experimental Therapeutics·Kirsten M RaehalLaura M Bohn
Mar 30, 2007·The Journal of Pharmacology and Experimental Therapeutics·Michael T GriffinFrederick J Ehlert
Oct 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·James W WislerRobert J Lefkowitz
Oct 1, 2008·The Journal of Pharmacology and Experimental Therapeutics·Katherine W FigueroaFrederick J Ehlert
May 10, 2011·Journal of Biomolecular Screening·Sarah A NickollsRoss A Kinloch
May 26, 2011·Molecular Pharmacology·Sudarshan RajagopalRobert J Lefkowitz
Oct 26, 2011·Proceedings of the National Academy of Sciences of the United States of America·John A AllenJian Jin
Jun 28, 2012·The Journal of Biological Chemistry·Marie-Laure RivesJonathan A Javitch
Aug 4, 2012·ACS Chemical Neuroscience·Terry KenakinSteven Novick
Sep 22, 2012·British Journal of Pharmacology·Terry Kenakin
Jan 10, 2013·The Journal of Pharmacology and Experimental Therapeutics·Scott M DeWireJonathan D Violin
Feb 16, 2013·Nature Reviews. Drug Discovery·Terry Kenakin, Arthur Christopoulos
Oct 22, 2013·Journal of Medicinal Chemistry·Jeremy ShonbergJ Robert Lane
Nov 16, 2013·Nucleic Acids Research·Adam J PawsonUNKNOWN NC-IUPHAR
Dec 21, 2013·British Journal of Pharmacology·M D HollenbergR Ramachandran
Jan 28, 2014·British Journal of Pharmacology·G L ThompsonM Canals
May 20, 2014·Current Opinion in Pharmacology·David H RomingerJonathan D Violin
Aug 15, 2014·The Journal of Biological Chemistry·Peishen ZhaoNigel W Bunnett
Dec 3, 2014·Trends in Biochemical Sciences·Arun K ShuklaEshan Ghosh
Dec 30, 2014·The Journal of Pharmacology and Experimental Therapeutics·Tarsis F BrustVal J Watts
Feb 15, 2015·Molecular Pharmacology·Edward L StahlLaura M Bohn
May 28, 2015·Molecular Pharmacology·Georgina L ThompsonMeritxell Canals
Jun 27, 2015·British Journal of Pharmacology·Michael J CurtisJohn C McGrath
Dec 10, 2015·British Journal of Pharmacology·Stephen Ph AlexanderUNKNOWN CGTP Collaborators
Dec 10, 2015·British Journal of Pharmacology·Stephen Ph AlexanderCgtp Collaborators
Dec 10, 2015·British Journal of Pharmacology·Stephen Ph AlexanderCgtp Collaborators

❮ Previous
Next ❯

Citations

Dec 31, 2016·Biomolecules & Therapeutics·Zuzana BolognaIl-Man Kim
Feb 8, 2018·SLAS Technology·Rosa M MellaPatricia Villacé
Mar 28, 2018·British Journal of Pharmacology·Rob HillGraeme Henderson
Jan 13, 2018·Molecular Pharmacology·Martin C Michel, Steven J Charlton
Aug 1, 2020·Archives of Toxicology·Marthe M VandeputteChristophe P Stove
Feb 24, 2019·Scientific Reports·Xiao ZhuStephen B Duffull
Mar 3, 2020·Frontiers in Pharmacology·John A ZebalaDean Y Maeda
Feb 16, 2020·International Journal of Molecular Sciences·Sarah PaisdziorPeter Kühnen
Jun 9, 2019·Molecular Pharmacology·Alexandra E Conibear, Eamonn Kelly
Sep 1, 2019·Biochemical Pharmacology·Elise WoutersChristophe P Stove
Oct 28, 2019·Biological Psychiatry·Aashish Manglik
Feb 20, 2021·Cellular Signalling·H Ongun Onaran, Tommaso Costa
Jun 22, 2021·ACS Pharmacology & Translational Science·Jin Hee LeeDo Sup Lee
Jul 13, 2021·Journal of Chemical Information and Modeling·Brendan KellyRon O Dror
Nov 3, 2016·Journal of Medicinal Chemistry·Xin ChenJian Jin
Aug 14, 2020·ACS Chemical Neuroscience·Anna E RinguetteAaron M Bender

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.